REFRACTORY MANTLE CELL LYMPHOMA
Clinical trials for REFRACTORY MANTLE CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MANTLE CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY MANTLE CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can nivolumab rescue patients when CAR T-Cell therapy fails?
Disease control CompletedThis phase 2 trial tested nivolumab, an immunotherapy drug, in 20 people with blood cancers like lymphoma, leukemia, or myeloma that came back or didn't respond after CAR T-cell therapy. The goal was to see if nivolumab could help the immune system attack the cancer again. The st…
Matched conditions: REFRACTORY MANTLE CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New hope for lymphoma patients after CAR T-Cell failure
Disease control CompletedThis study tested a drug called glofitamab in 67 people with certain types of lymphoma (a blood cancer) that did not respond to or came back after CAR T-cell therapy. Participants received a pre-treatment followed by up to 11 cycles of glofitamab. The goal was to see if this anti…
Matched conditions: REFRACTORY MANTLE CELL LYMPHOMA
Phase: PHASE2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug cocktail shows promise for Tough-to-Treat lymphoma
Disease control CompletedThis early-stage trial tested a combination of two drugs, lenalidomide and blinatumomab, in 35 adults with non-Hodgkin lymphoma that had come back or stopped responding to treatment. The main goal was to find the safest dose and understand side effects. Researchers also looked at…
Matched conditions: REFRACTORY MANTLE CELL LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC